Form 13-F position report

RANI THERAPEUTICS HLDGS INC

Reported by Bank of America Corporation

Company profile Manager portfolio Source filing
RANI CUSIP 753018100 Manager CIK 0000070858
Latest reported change

Reported 91,846 shares, down 32,659 (26.2%) from the prior quarter.

Reported value -9.9%; share count -26.2% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 91,846 Quarter-end amount reported
Reported value $349,015 Fair value at quarter end
Consecutive quarters held 12 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q1 2026 Reduced 0 -36,607 (-100.0%) 0 $0 2026-05-18
Q4 2025 Added 36,607 +18,855 (106.2%) < 0.01% $49,420 2026-02-17
Q3 2025 Reduced 17,752 -13,413 (-43.0%) < 0.01% $8,858 2025-11-14
Q2 2025 Reduced 31,165 -15,475 (-33.2%) < 0.01% $15,987 2025-08-14
Q1 2025 Reduced 46,640 -27,488 (-37.1%) < 0.01% $58,766 2025-05-15
Q4 2024 Reduced 74,128 -2,017 (-2.6%) < 0.01% $101,555 2025-02-14
Q3 2024 Reduced 76,145 -15,701 (-17.1%) < 0.01% $164,474 2024-11-14
Q2 2024 Reduced 91,846 -32,659 (-26.2%) < 0.01% $349,015 2024-08-14
Q1 2024 Added 124,505 +10,246 (9.0%) < 0.01% $387,211 2024-05-15
Q4 2023 Reduced 114,259 -92,862 (-44.8%) < 0.01% $379,340 2024-02-14
Q3 2023 Added 207,121 +34,831 (20.2%) < 0.01% $450,488 2023-11-14
Q2 2023 Added 172,290 +158,839 (1180.9%) < 0.01% $709,835 2023-08-14
Q1 2023 Added 13,451 +9,618 (250.9%) < 0.01% $69,407 2023-05-12
Q4 2022 Added 3,833 +1,110 (40.8%) < 0.01% $22,616 2023-02-10
Q3 2022 Added 2,723 +638 (30.6%) < 0.01% $27,000 2022-11-14
Q2 2022 Reduced 2,085 -1,070 (-33.9%) < 0.01% $21,000 2022-08-12
Q1 2022 Reduced 3,155 -1,267 (-28.7%) < 0.01% $42,000 2022-05-16
Q4 2021 Added 4,422 +2,955 (201.4%) < 0.01% $73,000 2022-02-08
Q3 2021 New 1,467 +1,467 (0.0%) < 0.01% $26,000 2021-11-15
Institutional context

Who else reported the position

41 managers reported RANI THERAPEUTICS HLDGS INC for Q2 2024.

Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 709,828 +24,525 < 0.01% $2,697,347 12 qtrs
Nan Fung Group Holdings Ltd Unchanged 493,584 0 2.0% $1,875,619 12 qtrs
Alphabet Inc Unchanged 448,492 0 0.09% $1,704,270 10 qtrs
UNITED SERVICES AUTOMOBILE ASSOCIATION Reduced 312,095 -169,205 0.03% $1,185,961 10 qtrs
TAKEDA PHARMACEUTICAL CO LTD Reduced 215,172 -123,507 0.35% $817,654 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 150,734 +19,828 < 0.01% $572,922 12 qtrs
STIFEL FINANCIAL CORP Added 134,620 +2,186 < 0.01% $511,556 12 qtrs
Bank of America Corporation This report Reduced 91,846 -32,659 < 0.01% $349,015 12 qtrs
BRIDGEWAY CAPITAL MANAGEMENT LLC Added 71,500 +20,000 < 0.01% $271,700 4 qtrs
BlackRock Inc Unchanged 63,583 0 < 0.01% $241,615 11 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM CL A

Voting authority reported

Sole
1,585
Shared
111
None
90,150

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.